相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks et al.
ANNALS OF ONCOLOGY (2020)
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors
Neelima Vidula et al.
CLINICAL CANCER RESEARCH (2020)
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
Andrew D. Simmons et al.
BMC CANCER (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers
Timothy A. Yap et al.
CANCER DISCOVERY (2020)
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Stephen J. Pettitt et al.
CANCER DISCOVERY (2020)
The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
Saya L. Jacob et al.
HELIYON (2020)
Isomerization of BRCA1-BARD1 promotes replication fork protection
Manuel Daza-Martin et al.
NATURE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok et al.
NATURE COMMUNICATIONS (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Yifan Wang et al.
NATURE COMMUNICATIONS (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
Erica L. Gornstein et al.
CLINICAL BREAST CANCER (2018)
Decoding non-random mutational signatures at Cas9 targeted sites
Amir Taheri-Ghahfarokhi et al.
NUCLEIC ACIDS RESEARCH (2018)
Targeting the replication stress response in cancer
Josep V. Forment et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Comprehensive Mapping of Histone Modifications at DNA Double-Strand Breaks Deciphers Repair Pathway Chromatin Signatures
Thomas Clouaire et al.
MOLECULAR CELL (2018)
Accurate classification of BRCA1 variants with saturation genome editing
Gregory M. Findlay et al.
NATURE (2018)
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
Jai N. Patel et al.
BRITISH JOURNAL OF CANCER (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L. Christie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Non-homologous DNA end joining and alternative pathways to double-strand break repair
Howard H. Y. Chang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
Robert L. Hollis et al.
ONCOTARGETS AND THERAPY (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance
Rachel W. Anantha et al.
ELIFE (2017)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2017)
BRCA1 reversion mutation acquired after treatment identified by liquid biopsy
Paul Mayor et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
Anosheh Afghahi et al.
CLINICAL CANCER RESEARCH (2017)
Targeting DNA-Dependent Protein Kinase for Cancer Therapy
Suzannah J. Harnor et al.
CHEMMEDCHEM (2017)
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
Michael J. Pishvaian et al.
BRITISH JOURNAL OF CANCER (2017)
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang et al.
CANCER RESEARCH (2016)
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Rinske Drost et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Essential Roles for Polymerase θ-Mediated End Joining in the Repair of Chromosome Breaks
David W. Wyatt et al.
MOLECULAR CELL (2016)
Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection
Ruth M. Densham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection
Ruth M. Densham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Hereditary breast and ovarian cancer: new genes in confined pathways
Finn Cilius Nielsen et al.
NATURE REVIEWS CANCER (2016)
Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
Timothy R. Rebbeck et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Raphael Ceccaldi et al.
NATURE (2015)
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Pedro A. Mateos-Gomez et al.
NATURE (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Louise J. Barber et al.
JOURNAL OF PATHOLOGY (2013)
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Neil Johnson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Rinske Drost et al.
CANCER CELL (2011)
Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
Katharina Schlacher et al.
CELL (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing
Quan Zhu et al.
NATURE (2011)
BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity
Reena Shakya et al.
SCIENCE (2011)
Plasticity of BRCA2 Function in Homologous Recombination: Genetic Interactions of the PALB2 and DNA Binding Domains
Nicolas Siaud et al.
PLOS GENETICS (2011)
Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt
Steffen Durinck et al.
NATURE PROTOCOLS (2009)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Improving sequence variant descriptions in mutation Databases and literature using the mutalyzer sequence variation nomenclature checker
Martin Wildeman et al.
HUMAN MUTATION (2008)
BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis
S Durinck et al.
BIOINFORMATICS (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Insights into DNA recombination from the structure of a RAD51-BRCA2 complex
L Pellegrini et al.
NATURE (2002)
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
J Jonkers et al.
NATURE GENETICS (2001)
分享论文
